Haematologica (Nov 2007)

Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study

  • Massimo Federico,
  • Cesare Guglielmi,
  • Stefano Luminari,
  • Caterina Mammi,
  • Luigi Marcheselli,
  • Umberto Gianelli,
  • Antonino Maiorana,
  • Francesco Merli,
  • Monica Bellei,
  • Samantha Pozzi,
  • Caterina Stelitano,
  • Antonio Lazzaro,
  • Paolo G. Gobbi,
  • Luca Baldini,
  • Stefania Bergantini,
  • Vittorio Fregoni,
  • Maura Brugiatelli

DOI
https://doi.org/10.3324/haematol.11502
Journal volume & issue
Vol. 92, no. 11

Abstract

Read online

Background and Objectives Although serum β2 microglobulin (β2 M) is an easy parameter to measure, and over-expressed in a large number of lymphoproliferative diseases, its prognostic value has been largely underestimated. The present study examined the influence of β2M levels on overall survival (OS) of patients with follicular lymphoma (FL).Design and Methods The prognostic role of β2M was evaluated in 236 patients with FL identified from the databases of the Gruppo Italiano per lo Studio dei Linfomi (GISL) and treated with anthracycline-based regimens from 1993 to 2003.Results Elevated serum β2M levels were found in 82 patients (35%). According to multivariate logistic regression analysis, elevated β2M levels were associated with elevated lactate dehydrogenase (LDH) (p=0.021), age (p=0.029), and number of involved nodal areas (p